Findings

What do systematic reviews say?

8 questions · 8 findings · 3 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 7 · 87.5%Very low 1 · 12.5%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Group C cognitive behavioural therapy: cognitive behavioural therapy + placebo vs placebo or supportive treatment

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

α‐FLUPENTHIXOL vs PLACEBO or β‐FLUPENTHIXOL

Mental state and behaviour: clinically important change in general mental state and behaviour · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus placebo for schizophrenia 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
GRADE not reported

Omega‐3 vs placebo

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group B antipsychotic drugs: olanzapine + supportive intervention vs placebo or supportive treatment

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo and cognitive and behavioural therapies

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group A: amino acids vs placebo

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo or supportive treatment

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

ARIPIPRAZOLE (IM) vs PLACEBO/NIL

Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

It is very uncertain whether ARIPIPRAZOLE (IM) changes specific behaviour: Agitation ‐ clinically important change (PANSS… compared with PLACEBO/NIL (very low certainty).

1 finding from 1 review

Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation) 2018 · Cochrane Headline outcomes only
RR 1.5 [1.17, 1.92]
2 studies · 382 participants
Very low